Waivers remove requirement to conduct pediatric clinical studies to support cosibelimab marketing authorization applications in…
POINT’s manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for…
PHILADELPHIA, PA, May 13, 2022 (GLOBE NEWSWIRE) — Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or…
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) submitted to U.S. Food and Drug Administration…
CAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset…
VANCOUVER, Washington, May 13, 2022 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the…
SEATTLE and VANCOUVER, British Columbia, May 13, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc….
Conference call scheduled for 8:30 a.m. ET today MIAMI, May 13, 2022 (GLOBE NEWSWIRE) —…
Announced oral presentation of TPST-1120 Phase 1 monotherapy and combination therapy data at ASCO Presented…
BILLERICA, Mass., May 13, 2022 (GLOBE NEWSWIRE) — SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ:…
Nyxol Posts 5 Positive Clinical Data Readouts Including Presbyopia in Last 12 Months Successfully Enrolled…
MILAN, Italy and NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) — Genenta Science (NASDAQ: GNTA),…
Statera expects to acquire option to license Lay Sciences products for respiratory & gastrointestinal disorders…
Expands rare cannabinoid portfolio with the addition of CBT and CBDV Strengthens IP with publication…
–Entered into a definitive agreement to sell the rare pediatric disease Priority Review Voucher (PRV)…
TORONTO, May 13, 2022 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:…
PURCHASE, N.Y., May 13, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience…
Disposition of MPS programs to reduce operating expenses and extend projected cash runway into 2Q 2023…
MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW…
DUBLIN, Ireland, May 13, 2022 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical…